Cargando…

Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA

Breast cancer exhibits various epigenetic abnormalities that regulate gene expression and contribute to tumor characteristics. Epigenetic alterations play a significant role in cancer development and progression, and epigenetic-targeting drugs such as DNA methyltransferase inhibitors, histone-modify...

Descripción completa

Detalles Bibliográficos
Autores principales: Szczepanek, Joanna, Skorupa, Monika, Jarkiewicz-Tretyn, Joanna, Cybulski, Cezary, Tretyn, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138995/
https://www.ncbi.nlm.nih.gov/pubmed/37108398
http://dx.doi.org/10.3390/ijms24087235
_version_ 1785032839309295616
author Szczepanek, Joanna
Skorupa, Monika
Jarkiewicz-Tretyn, Joanna
Cybulski, Cezary
Tretyn, Andrzej
author_facet Szczepanek, Joanna
Skorupa, Monika
Jarkiewicz-Tretyn, Joanna
Cybulski, Cezary
Tretyn, Andrzej
author_sort Szczepanek, Joanna
collection PubMed
description Breast cancer exhibits various epigenetic abnormalities that regulate gene expression and contribute to tumor characteristics. Epigenetic alterations play a significant role in cancer development and progression, and epigenetic-targeting drugs such as DNA methyltransferase inhibitors, histone-modifying enzymes, and mRNA regulators (such as miRNA mimics and antagomiRs) can reverse these alterations. Therefore, these epigenetic-targeting drugs are promising candidates for cancer treatment. However, there is currently no effective epi-drug monotherapy for breast cancer. Combining epigenetic drugs with conventional therapies has yielded positive outcomes and may be a promising strategy for breast cancer therapy. DNA methyltransferase inhibitors, such as azacitidine, and histone deacetylase inhibitors, such as vorinostat, have been used in combination with chemotherapy to treat breast cancer. miRNA regulators, such as miRNA mimics and antagomiRs, can alter the expression of specific genes involved in cancer development. miRNA mimics, such as miR-34, have been used to inhibit tumor growth, while antagomiRs, such as anti-miR-10b, have been used to inhibit metastasis. The development of epi-drugs that target specific epigenetic changes may lead to more effective monotherapy options in the future.
format Online
Article
Text
id pubmed-10138995
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101389952023-04-28 Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA Szczepanek, Joanna Skorupa, Monika Jarkiewicz-Tretyn, Joanna Cybulski, Cezary Tretyn, Andrzej Int J Mol Sci Review Breast cancer exhibits various epigenetic abnormalities that regulate gene expression and contribute to tumor characteristics. Epigenetic alterations play a significant role in cancer development and progression, and epigenetic-targeting drugs such as DNA methyltransferase inhibitors, histone-modifying enzymes, and mRNA regulators (such as miRNA mimics and antagomiRs) can reverse these alterations. Therefore, these epigenetic-targeting drugs are promising candidates for cancer treatment. However, there is currently no effective epi-drug monotherapy for breast cancer. Combining epigenetic drugs with conventional therapies has yielded positive outcomes and may be a promising strategy for breast cancer therapy. DNA methyltransferase inhibitors, such as azacitidine, and histone deacetylase inhibitors, such as vorinostat, have been used in combination with chemotherapy to treat breast cancer. miRNA regulators, such as miRNA mimics and antagomiRs, can alter the expression of specific genes involved in cancer development. miRNA mimics, such as miR-34, have been used to inhibit tumor growth, while antagomiRs, such as anti-miR-10b, have been used to inhibit metastasis. The development of epi-drugs that target specific epigenetic changes may lead to more effective monotherapy options in the future. MDPI 2023-04-13 /pmc/articles/PMC10138995/ /pubmed/37108398 http://dx.doi.org/10.3390/ijms24087235 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Szczepanek, Joanna
Skorupa, Monika
Jarkiewicz-Tretyn, Joanna
Cybulski, Cezary
Tretyn, Andrzej
Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA
title Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA
title_full Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA
title_fullStr Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA
title_full_unstemmed Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA
title_short Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA
title_sort harnessing epigenetics for breast cancer therapy: the role of dna methylation, histone modifications, and microrna
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138995/
https://www.ncbi.nlm.nih.gov/pubmed/37108398
http://dx.doi.org/10.3390/ijms24087235
work_keys_str_mv AT szczepanekjoanna harnessingepigeneticsforbreastcancertherapytheroleofdnamethylationhistonemodificationsandmicrorna
AT skorupamonika harnessingepigeneticsforbreastcancertherapytheroleofdnamethylationhistonemodificationsandmicrorna
AT jarkiewicztretynjoanna harnessingepigeneticsforbreastcancertherapytheroleofdnamethylationhistonemodificationsandmicrorna
AT cybulskicezary harnessingepigeneticsforbreastcancertherapytheroleofdnamethylationhistonemodificationsandmicrorna
AT tretynandrzej harnessingepigeneticsforbreastcancertherapytheroleofdnamethylationhistonemodificationsandmicrorna